NCT03470259 - Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions

Papillary Thyroid CancerLymph Node Metastases

Interventions

DRUG

IV adminstration of EMI-137

Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.

DEVICE

Multispectral Fluorescence Reflectance Imaging

A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.

DEVICE

Spectroscopy

A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.

Trial Locations (2)

9713GZ

University Medical Center Groningen, Groningen

Unknown

Erasmus Medical Center, Rotterdam